Eledon Pharmaceuticals, Inc. (ELDN)
Largest Insider Buys in Sector
ELDN Stock Price History Chart
ELDN Stock Performance
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the …
Insider Activity of Eledon Pharmaceuticals, Inc.
Over the last 12 months, insiders at Eledon Pharmaceuticals, Inc. have bought $4.57M and sold $0 worth of Eledon Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Eledon Pharmaceuticals, Inc. have bought $2.33M and sold $1.29M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BVF PARTNERS L P/IL (10 percent owner) — $86.82M.
The last purchase of 1,927,937 shares for transaction amount of $4.57M was made by BVF PARTNERS L P/IL (10 percent owner) on 2024‑05‑09.
List of Insider Buy and Sell Transactions, Eledon Pharmaceuticals, Inc.
| 2024-05-09 | 10 percent owner | 1.93M 7.8677% | $2.37 | $4.57M | +15.40% | |||
| 2023-05-05 | 10 percent owner | 1.98M 11.9399% | $2.31 | $4.57M | -41.42% | |||
| 2022-11-23 | President | 1,000 0.0072% | $2.60 | $2,597 | -23.11% | |||
| 2021-12-20 | Chief Executive Officer | 2,000 0.0135% | $4.48 | $8,960 | -30.07% | |||
| 2021-08-17 | Chief Executive Officer | 4,000 0.0262% | $6.21 | $24,840 | -39.06% | |||
| 2021-06-11 | CHIEF FINANCIAL OFFICER | 10,000 0.0681% | $8.87 | $88,700 | -46.53% | |||
| 2021-06-09 | Chief Executive Officer | 3,000 0.0203% | $8.01 | $24,030 | -40.88% | |||
| 2020-12-02 | Sale | 10 percent owner | 103,200 6.5689% | $21.60 | $2.23M | -63.07% | ||
| 2020-10-30 | Sale | 10 percent owner | 12,969 0.9094% | $26.64 | $345,559 | -62.38% | ||
| 2020-10-30 | 10 percent owner | 92,040 6.1626% | $25.44 | $2.34M | -62.38% | |||
| 2019-05-21 | Sale | Chief Executive Officer | 2,937 0.025% | $1.91 | $5,614 | -66.49% | ||
| 2019-05-21 | Sale | President | 1,914 0.0163% | $1.91 | $3,658 | -66.49% | ||
| 2019-05-21 | Sale | See Remarks | 1,058 0.009% | $1.91 | $2,022 | -66.49% | ||
| 2019-05-20 | Sale | Chief Executive Officer | 11,701 0.1045% | $1.96 | $22,953 | -65.78% | ||
| 2019-05-20 | Sale | President | 7,623 0.068% | $1.96 | $14,953 | -65.78% | ||
| 2019-05-20 | Sale | See Remarks | 4,218 0.0377% | $1.96 | $8,274 | -65.78% | ||
| 2019-05-02 | 646,204 6.2443% | $3.10 | $2M | -76.19% | ||||
| 2019-05-02 | director | 646,204 6.2443% | $3.10 | $2M | -76.19% | |||
| 2019-04-30 | Sale | 10 percent owner | 200 0.0017% | $2.70 | $540 | -75.47% | ||
| 2018-09-12 | President | 16,632 0.1711% | $5.02 | $83,476 | -44.40% |
Insider Historical Profitability
| BVF PARTNERS L P/IL | 10 percent owner | 3361803 5.795% | $5.09 | 2 | 0 | <0.0001% |
| Harrison Seth Loring | 7912079 13.6387% | $5.09 | 1 | 0 | ||
| Novartis Bioventures Ltd | 10 percent owner | 4493458 7.7458% | $5.09 | 1 | 9 | |
| Apple Tree Partners II - Annex, L.P. | 3568438 6.1512% | $5.09 | 1 | 0 | ||
| Chimovits Erez | director | 3183314 5.4873% | $5.09 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Bvf Inc Il | $8.91M | 11.24 | 4.33M | 0% | +$0 | 0.07 | |
| Armistice Capital Llc | $4.73M | 5.97 | 2.3M | +4.93% | +$222,480.00 | 0.02 | |
| The Vanguard Group | $2M | 2.52 | 969,121 | +39.36% | +$563,828.11 | <0.0001 | |
| Woodline Partners LP | $1.34M | 1.69 | 651,939 | -5.43% | -$77,046.04 | 0.01 | |
| Ensign Peak Advisors Inc | $912,582.00 | 1.15 | 443,001 | 0% | +$0 | <0.01 |